What question did this study set out to answer?

Evaluate the feasibility and efficacy of molecularly adapted therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results

View Full Paper

Ask AI

Bookmark

Authors

This prospective study demonstrates high response rates in newly diagnosed DLBCL with a genotype-directed therapy, suggesting better outcomes.

Evaluate the feasibility and efficacy of molecularly adapted therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Single-center, prospective, non-randomized study with 43 adults diagnosed with DLBCL.
Participants underwent tumor genotyping using a 19-gene or a 60-gene panel.
Initial R-CHOP therapy was followed by R-CHOP-X, incorporating agents based on molecular subtype.
Response assessed via PET/CT and adverse events recorded per NCI CTCAE v5.0.
Overall response rate was 100% with complete response rate also at 100% among those who finished therapy.
At two years, overall survival was 92% and progression-free survival was 94%.
Use of a 60-gene panel significantly reduced unclassifiable cases from 34% to 12%.
Notable adverse events included grade 3–4 neutropenia (26%) and thrombocytopenia (12%), but no treatment discontinuations were noted.

Mingalimov et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

This prospective study demonstrates high response rates in newly diagnosed DLBCL with a genotype-directed therapy, suggesting better outcomes.

Evaluate the feasibility and efficacy of molecularly adapted therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Single-center, prospective, non-randomized study with 43 adults diagnosed with DLBCL.
Participants underwent tumor genotyping using a 19-gene or a 60-gene panel.
Initial R-CHOP therapy was followed by R-CHOP-X, incorporating agents based on molecular subtype.
Response assessed via PET/CT and adverse events recorded per NCI CTCAE v5.0.
Overall response rate was 100% with complete response rate also at 100% among those who finished therapy.
At two years, overall survival was 92% and progression-free survival was 94%.
Use of a 60-gene panel significantly reduced unclassifiable cases from 34% to 12%.
Notable adverse events included grade 3–4 neutropenia (26%) and thrombocytopenia (12%), but no treatment discontinuations were noted.

Mingalimov et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark